Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Societal Costs of Sickle Cell Disease in the United States

Irene Agodoa, MD, Deborah Lubeck, PhD, Nickhill Bhakta, MD MPH, Mark Danese, MHS, PhD, Kartik Pappu, PhD, Robin Howard, MBA, Michelle Gleeson, PhD, Marc Halperin, BA, Sophie Lanzkron, MD MHS

Blood (2018) 132 (Supplement 1): 4706.

https://doi.org/10.1182/blood-2018-99-119420

Published: 2018

Journal Articles

Incidence Of Comorbidities In Medicare Beneficiaries Diagnosed With Acute Lymphoblastic Leukemia

Kara Cetin, MPH, Mark Danese, PhD, Aaron J Katz, PharmD, PhD, Michael A Kelsh, PhD, MPH, Michelle Gleeson, PhD, Shilpa S. Alekar, MD, Robert Griffiths, MS, ScD

Blood (2013) 122 (21): 4989.

https://doi.org/10.1182/blood.V122.21.4989.4989

Published: 2013

Journal Articles

Patterns Of Care, Survival, and Costs Of Second-Line Treatment In Medicare Beneficiaries With Diffuse Large B-Cell Lymphoma (DLBCL)

Mark Danese, PhD, Robert Griffiths, MS, ScD, Michelle Gleeson, PhD, Tapashi Dalvi, PhD, Jingyi Li, PhD, MS, MB, Robert G Deeter, PharmD, Joseph R. Mikhael, MD, Martin Dreyling

Blood (2013) 122 (21): 2936.

https://doi.org/10.1182/blood.V122.21.2936.2936

Published: 2013

Journal Articles

How Many Life Years Have Been Saved In The United States From Using Rituximab Plus Chemotherapy Compared To Chemotherapy Alone From 1998-2013

Mark Danese, PhD, Michelle Gleeson, PhD, Marc Halperin, Sandra Skettino, M.D., Carolina Reyes, PhD

Blood (2013) 122 (21): 2937.

https://doi.org/10.1182/blood.V122.21.2937.2937

Published: 2013

Journal Articles

Patterns Of Care In Medicare Beneficiaries Diagnosed With Acute Lymphoblastic Leukemia

Mark Danese, PhD, Kara Cetin, MPH, Aaron J Katz, PharmD, PhD, Michael A Kelsh, PhD, MPH, Michelle Gleeson, PhD, Robert Griffiths, MS, ScD

Blood (2013) 122 (21): 3877.

https://doi.org/10.1182/blood.V122.21.3877.3877

Published: 2013

Journal Articles

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma

Robert Griffiths, Joseph Mikhael, Michelle Gleeson, Mark Danese, Martin Dreyling

Blood (2011) 118 (18): 4808–4816.

https://doi.org/10.1182/blood-2011-04-348367

Published: 2011

Journal Articles

An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia

Mark D. Danese, Robert I. Griffiths, Michelle Gleeson, Sacha Satram-Hoang, Kevin Knopf, Joseph Mikhael, Carolina Reyes

Blood (2011) 117 (13): 3505–3513.

https://doi.org/10.1182/blood-2010-08-301929

Published: 2011

Includes: Supplemental data

Journal Articles

Patterns and Outcomes of Infused Therapy for Chronic Lymphocytic Leukemia (CLL) in a Medicare Population.

Robert Griffiths, ScD, Carolina Reyes, PhD, Michelle Gleeson, PhD, Kevin Knopf, MD, Mark Danese, PhD

Blood (2009) 114 (22): 4409.

https://doi.org/10.1182/blood.V114.22.4409.4409

Published: 2009

Journal Articles

Evaluation of Bleeding-Related Episodes in Patients with Chronic Immune Thrombocytopenia (ITP) Treated with Romiplostim in Two Phase 3 Placebo-Controlled Clinical Trials.

Ilene Ceil Weitz, MD, Miguel A Sanz, David H. Henry, MD, Martin Schipperus, Bertrand Godeau, Michelle Gleeson, PhD, Mark Danese, Robert Deuson, PhD

Blood (2009) 114 (22): 891.

https://doi.org/10.1182/blood.V114.22.891.891

Published: 2009

Journal Articles

Patterns of Chemotherapy/Immunotherapy and Survival in Mantle Cell Lymphoma: Evidence from SEER-Medicare

Robert Griffiths, ScD, Mark Danese, MHS, PhD, Michelle Gleeson, PhD, Kevin Knopf, MD

Blood (2008) 112 (11): 5293.

https://doi.org/10.1182/blood.V112.11.5293.5293

Published: 2008

Journal Articles

Validating the Follicular Lymphoma International Prognostic Index (FLIPI) Using SEER-Medicare Claims Data

Mark Danese, MHS, PhD, Robert Griffiths, ScD, Michelle Gleeson, PhD, Kevin Knopf, MD

Blood (2008) 112 (11): 872.

https://doi.org/10.1182/blood.V112.11.872.872

Published: 2008

NARROW

Societal Costs of Sickle Cell Disease in the United States

Incidence Of Comorbidities In Medicare Beneficiaries Diagnosed With Acute Lymphoblastic Leukemia

Patterns Of Care, Survival, and Costs Of Second-Line Treatment In Medicare Beneficiaries With Diffuse Large B-Cell Lymphoma (DLBCL)

How Many Life Years Have Been Saved In The United States From Using Rituximab Plus Chemotherapy Compared To Chemotherapy Alone From 1998-2013

Patterns Of Care In Medicare Beneficiaries Diagnosed With Acute Lymphoblastic Leukemia

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma

An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia

Patterns and Outcomes of Infused Therapy for Chronic Lymphocytic Leukemia (CLL) in a Medicare Population.

Evaluation of Bleeding-Related Episodes in Patients with Chronic Immune Thrombocytopenia (ITP) Treated with Romiplostim in Two Phase 3 Placebo-Controlled Clinical Trials.

Patterns of Chemotherapy/Immunotherapy and Survival in Mantle Cell Lymphoma: Evidence from SEER-Medicare

Validating the Follicular Lymphoma International Prognostic Index (FLIPI) Using SEER-Medicare Claims Data

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only